Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients` quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Its product portfolio includes digestive health products, including enteral feeding tubes and solutions; respiratory health products, such as closed airway suction systems and oral care kits; and acute pain products comprising surgical pain pumps, and cold and compression therapy systems, as well as interventional pain management solutions that include minimally invasive interventional pain therapies. The company sells its products under the MIC-KEY, CORPAK, NEOMED, BALLARD, MICROCUFF, ENDOCLEAR, ON-Q, AMBIT, GAME READY, and COOLIEF brand names. It markets its products directly to hospitals and other healthcare providers, and through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Website: avanos.com



Growth: Pretty weak revenue growth rate 4.7%, there is acceleration compared to average historical growth rates -3.6%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -63.1%. On average the margin is decreasing steadily. Gross margin is high, +45.6%. In the last quarter the company beat the estimated EPS, 0.0%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 9.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 17.9% higher than minimum and 63.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.6x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.2 mln (-0.032% of cap.)

Key Financials (Download financials)

Ticker: AVNS
Share price, USD:  (+2.5%)11.66
year average price 13.09  


year start price 18.44 2024-12-12

max close price 18.44 2024-12-12

min close price 9.89 2025-08-05

current price 11.66 2025-12-11
Common stocks: 46 279 106

Dividend Yield:  0.0%
Last revenue growth (y/y):  +4.7%
Last growth of EBITDA (y/y):  -58.3%
Historical revenue growth:  -3.6%
Historical growth of EBITDA:  -18.6%
EV / Sales: 0.9x
Margin (EBITDA LTM / Revenue): -63.1%
Fundamental value created in LTM:
Market Cap ($m): 540
Net Debt ($m): 63
EV (Enterprise Value): 603
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-12-05zacks.com

Why Is Avanos Medical (AVNS) Down 0.5% Since Last Earnings Report?

2025-11-06zacks.com

Avanos Medical Gains on Q3 Earnings Beat, Raises '25 Sales View

2025-11-05seekingalpha.com

Avanos Medical, Inc. (AVNS) Q3 2025 Earnings Call Transcript

2025-11-05zacks.com

Avanos Medical (AVNS) Q3 Earnings and Revenues Beat Estimates

2025-10-05seekingalpha.com

Avanos Medical: After Transformation Efforts, I Expect Inorganic Growth To Push The Price Up

2025-09-10zacks.com

Reasons to Retain Avanos Medical Stock in Your Portfolio Now

2025-08-06zacks.com

Avanos Medical Stock Down as Q2 Earnings Miss Estimates, Margins Down

2025-08-05seekingalpha.com

Avanos Medical, Inc. (AVNS) Q2 2025 Earnings Call Transcript

2025-08-05zacks.com

Avanos Medical (AVNS) Misses Q2 Earnings Estimates

2025-08-05prnewswire.com

Avanos Medical Announces Appointment of Scott Galovan as Senior Vice President, Chief Financial Officer; David Pacitti Appointed to Board of Directors
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-05 2024-10-30 2024-07-31 2024-05-02 2024-02-21 2023-11-01 2023-08-09 2023-05-03 2023-02-21 2022-11-02
acceptedDate 2025-11-05 16:28:31 2025-08-05 16:10:21 2024-10-30 16:17:20 2024-07-31 11:21:24 2024-05-02 16:10:10 2024-02-20 18:33:29 2023-11-01 16:09:09 2023-08-09 16:37:08 2023-05-03 16:21:26 2023-02-21 16:52:56 2022-11-02 16:08:59
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 178M 175M 170M 172M 166M 173M 171M 169M 192M 218M 202M
costOfRevenue 97M 83M 78M 76M 71M 76M 76M 72M 87M 101M 92M
grossProfit 81M 92M 93M 96M 95M 97M 96M 98M 105M 117M 110M
grossProfitRatio 0.456 0.526 0.545 0.557 0.571 0.562 0.558 0.577 0.545 0.537 0.545
researchAndDevelopmentExpenses 6M 6M 7M 6M 7M 7M 6M 7M 8M 8M 7M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 62M 79M 74M 73M 80M 68M 79M 93M 93M 83M 82M
otherExpenses 0 0 0 8M 0 -1M 0 0 1M 600 000 2M
operatingExpenses 68M 85M 76M 80M 87M 75M 94M 100M 102M 91M 91M
costAndExpenses 165M 168M 154M 156M 159M 151M 170M 172M 189M 191M 183M
interestIncome 500 000 600 000 700 000 3M 600 000 1 000 000 900 000 500 000 500 000 700 000 300 000
interestExpense 2M 2M 3M 3M 3M 3M 5M 4M 4M 3M 3M
depreciationAndAmortization 9M 10M 12M 11M 11M 43 812 11M 12M 13M 14M 12M
ebitda 10M -64M 24M 23M 19M 34M 13M 10M 15M 40M 31M
ebitdaratio 0.056 -0.365 0.143 0.16 0.113 0.194 0.076 0.058 0.079 0.185 0.151
operatingIncome 13M 7M 12M 16M 7M 22M 1M -2M 3M 26M 19M
operatingIncomeRatio 0.074 0.042 0.07 0.094 0.045 0.128 0.007 -0.012 0.014 0.12 0.093
totalOtherIncomeExpensesNet -14M -83M -3M -100 000 -6M -13M -4M -3M -3M -2M -3M
incomeBeforeTax -1M -76M 10M 6M 2M 9M -3M -5M -400 000 24M 16M
incomeBeforeTaxRatio -0.007 -0.434 0.056 0.036 0.009 0.051 -0.015 -0.03 -0.002 0.11 0.079
incomeTaxExpense 200 000 900 000 4M 2M 1 000 000 -2M 6M -800 000 100 000 7M 300 000
netIncome -1M -77M 4M 2M -900 000 11M -4M -68M -500 000 17M 16M
netIncomeRatio -0.008 -0.439 0.025 0.01 -0.005 0.061 -0.022 -0.402 -0.003 0.078 0.078
eps -0.03 -1.66 0.094 0.039 -0.02 0.23 -0.079 -1.46 -0.011 0.36 0.34
epsdiluted -0.03 -1.66 0.092 0.039 -0.02 0.23 -0.079 -1.46 -0.011 0.36 0.33
weightedAverageShsOut 46M 46M 46M 46M 46M 46M 47M 47M 47M 47M 47M
weightedAverageShsOutDil 46M 47M 47M 46M 46M 47M 47M 47M 47M 47M 47M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-05 2024-10-30 2024-07-31 2024-05-02 2024-02-21 2023-11-01 2023-08-09 2023-05-03 2023-02-21 2022-11-02
acceptedDate 2025-11-05 16:28:31 2025-08-05 16:10:21 2024-10-30 16:17:20 2024-07-31 11:21:24 2024-05-02 16:10:10 2024-02-20 18:33:29 2023-11-01 16:09:09 2023-08-09 16:37:08 2023-05-03 16:21:26 2023-02-21 16:52:56 2022-11-02 16:08:59
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 71M 90M 89M 92M 76M 88M 107M 82M 96M 128M 117M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 71M 90M 89M 92M 76M 88M 107M 82M 96M 128M 117M
netReceivables 111M 110M 132M 123M 131M 143M 145M 152M 143M 168M 146M
inventory 151M 143M 162M 164M 166M 163M 157M 148M 200M 190M 194M
otherCurrentAssets 19M 13M 90M 95M 95M 93M 14M 16M 15M 14M 13M
totalCurrentAssets 351M 356M 473M 474M 468M 487M 525M 507M 454M 500M 470M
propertyPlantEquipmentNet 145M 145M 136M 140M 140M 144M 144M 152M 192M 195M 196M
goodwill 394M 381M 795M 794M 795M 796M 792M 763M 822M 819M 824M
intangibleAssets 122M 105M 220M 226M 233M 240M 242M 223M 245M 251M 259M
goodwillAndIntangibleAssets 516M 487M 1 015M 1 021M 1 028M 1 036M 1 034M 985M 1 066M 1 070M 1 082M
longTermInvestments 0 0 0 -1 0 0 0 0 0 0 0
taxAssets 0 25M 7M 6M 6M 7M 4M 4M 5M 5M 11M
otherNonCurrentAssets 55M 26M 26M 17M 19M 19M 18M 19M 19M 18M 16M
totalNonCurrentAssets 716M 683M 1 184M 1 184M 1 194M 1 205M 1 200M 1 160M 1 281M 1 287M 1 305M
otherAssets 0 0 0 1 0 0 0 0 0 0 0
totalAssets 1 068M 1 039M 1 656M 1 658M 1 661M 1 692M 1 725M 1 667M 1 735M 1 787M 1 775M
accountPayables 54M 49M 54M 51M 57M 56M 52M 65M 60M 68M 63M
shortTermDebt 19M 20M 23M 39M 21M 21M 19M 20M 18M 19M 20M
taxPayables 0 6M 6M 6M 18M 17M 10M 6M 21M 21M 10M
deferredRevenue 0 0 0 1 18M 0 97M 73M 0 0 0
otherCurrentLiabilities 75M 61M 129M 112M 110M 157M 3M 3M 81M 99M 80M
totalCurrentLiabilities 148M 135M 213M 208M 205M 235M 171M 161M 159M 186M 162M
longTermDebt 115M 118M 179M 194M 167M 159M 288M 234M 237M 261M 285M
deferredRevenueNonCurrent 0 0 0 29M 27M 28M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 6M 24M 23M 24M 24M 29M 22M 25M 25M 37M
otherNonCurrentLiabilities 27M 4M 11M 11M 11M 10M 16M 15M 16M 24M 267M
totalNonCurrentLiabilities 142M 128M 214M 228M 228M 222M 332M 271M 278M 310M 349M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 31M 32M 40M 43M 27M 28M 42M 44M 45M 48M 50M
totalLiabilities 290M 263M 427M 436M 433M 456M 503M 432M 436M 496M 512M
preferredStock 0 0 0 0 0 341M 0 0 0 0 0
commonStock 500 000 500 000 500 000 500 000 500 000 500 000 500 000 500 000 500 000 500 000 500 000
retainedEarnings -779M -777M -310M -314M -316M -315M -325M -322M -253M -253M -270M
accumulatedOtherComprehensiveIncomeLoss -33M -32M -37M -38M -30M -27M -33M -28M -36M -36M -43M
othertotalStockholdersEquity 1 589M 1 585M 1 576M 1 573M 1 573M 1 236M 1 580M 1 584M 1 587M 1 580M 1 576M
totalStockholdersEquity 778M 776M 1 230M 1 222M 1 228M 1 236M 1 222M 1 235M 1 299M 1 291M 1 264M
totalEquity 778M 776M 1 230M 1 222M 1 228M 1 236M 1 222M 1 235M 1 299M 1 291M 1 264M
totalLiabilitiesAndStockholdersEquity 1 068M 1 039M 1 656M 1 658M 1 661M 1 692M 1 725M 1 667M 1 735M 1 787M 1 775M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 068M 1 039M 1 656M 1 658M 1 661M 1 692M 1 725M 1 667M 1 735M 1 787M 1 775M
totalInvestments 0 0 0 -1 0 0 0 0 0 0 0
totalDebt 134M 137M 202M 218M 215M 209M 307M 254M 255M 280M 304M
netDebt 63M 47M 113M 126M 139M 121M 200M 172M 160M 152M 187M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS AVNS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-05 2024-10-30 2024-07-31 2024-05-02 2024-02-21 2023-11-01 2023-08-09 2023-05-03 2023-02-21 2022-11-02
acceptedDate 2025-11-05 16:28:31 2025-08-05 16:10:21 2024-10-30 16:17:20 2024-07-31 11:21:24 2024-05-02 16:10:10 2024-02-20 18:33:29 2023-11-01 16:09:09 2023-08-09 16:37:08 2023-05-03 16:21:26 2023-02-21 16:52:56 2022-11-02 16:08:59
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -1M -77M 4M 4M 500 000 11M -4M -68M -500 000 17M 16M
depreciationAndAmortization 9M 10M 12M 11M 11M 12M 11M 12M 12M 13M 12M
deferredIncomeTax 0 0 0 10M 0 -7M -4M 0 0 300 000 0
stockBasedCompensation 0 4M 3M 4M 4M 4M 4M 4M 4M 4M 4M
changeInWorkingCapital -3M -7M 4M 11M -22M -3M 21M -13M -19M -2M -4M
accountsReceivables 700 000 -3M -8M -7M 8M 9M 11M -7M 26M -19M 900 000
inventory -500 000 -3M 2M -3M -5M 11M 7M -5M -9M 5M -19M
accountsPayables 1M 5M -1M -2M 2M 2M -14M 6M -8M 1M 600 000
otherWorkingCapital -4M -5M 11M 24M -28M -25M 17M -8M -29M 11M 13M
otherNonCashItems 9M 76M 700 000 37M 20M -4M 1M 64M -3M 700 000 400 000
netCashProvidedByOperatingActivities 14M 7M 23M 28M -8M 13M 29M -3M -7M 34M 28M
investmentsInPropertyPlantAndEquipment -7M -11M -3M -6M -4M -6M -4M -4M -4M -5M -5M
acquisitionsNet 0 -2M 0 0 2M 87M -45M 0 0 -116M 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites -25M 0 -9M -6M 2M 89M -45M -3M 0 116M 600 000
netCashUsedForInvestingActivites -32M -13M -12M -6M -2M 81M -49M -7M -4M -5M -5M
debtRepayment -2M -2M -13M -2M -8M -97M -55M -2M -22M -22M -19M
commonStockIssued 300 000 0 0 0 500 000 -200 000 900 000 0 0 100 000 0
commonStockRepurchased 0 -800 000 -100 000 -4M -9M -6M -9M -3M -1M -400 000 -11M
dividendsPaid 0 0 0 0 0 0 0 0 0 -226M 0
otherFinancingActivites 0 0 -3M 0 -500 000 -12M 166M 0 600 000 226M 20M
netCashUsedProvidedByFinancingActivities -2M -3M -16M -5M -700 000 -115M 47M -4M -22M -22M -10M
effectOfForexChangesOnCash -300 000 3M 2M -500 000 -1M 2M -2M -700 000 900 000 4M -3M
netChangeInCash -20M -7M -3M 16M -12M -19M 25M -14M -32M 11M 11M
cashAtEndOfPeriod 71M 90M 89M 92M 76M 88M 107M 82M 96M 128M 117M
cashAtBeginningOfPeriod 90M 97M 92M 76M 88M 107M 82M 96M 128M 117M 107M
operatingCashFlow 14M 7M 23M 28M -8M 13M 29M -3M -7M 34M 28M
capitalExpenditure -7M -11M -3M -6M -4M -6M -4M -4M -4M -5M -5M
freeCashFlow 7M -4M 20M 22M -12M 7M 25M -7M -11M 29M 23M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-11-05 ET (fiscal 2025 q3)
2025 q2
2025-08-05 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-05 ET (fiscal 2024 q1)
2023 q4
2024-02-20 ET (fiscal 2023 q4)
2023 q3
2023-11-04 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-21 ET (fiscal 2022 q4)
2022 q3
2022-11-05 ET (fiscal 2022 q3)
2022 q2
2022-08-12 ET (fiscal 2022 q2)
2022 q1
2022-05-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-30 10:45 ET
Avanos Medical, Inc. Announces Third Quarter 2024 Results, retirement of CEO
2024-10-23 10:19 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
2024-09-09 14:54 ET
Avanos Medical, Inc. to Present at the 2024 CL King Annual Best Ideas Conference
2024-09-09 14:29 ET
GAME READY® Announces Partnership with NFL Defensive End and 49ers Star Nick Bosa
2024-07-31 11:00 ET
Avanos Medical, Inc. Announces Second Quarter 2024 Results
2024-07-24 22:14 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
2024-07-01 11:00 ET
Avanos Medical, Inc. Appoints Indrani Franchini to Board of Directors
2024-05-13 11:15 ET
Avanos Medical, Inc. Appoints Sig Delgado as Senior Vice President, Integrated Supply Chain
2024-05-02 11:00 ET
Avanos Medical, Inc. Announces First Quarter 2024 Results
2024-04-25 15:16 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2024 Financial Results
2024-02-22 00:18 ET
Avanos Medical, Inc. Announces Voluntary Recall in Response to Nurse Assist, LLC Sterile Water Medical Products Recall
2024-02-20 12:00 ET
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2023 Results
2024-02-14 01:41 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
2024-01-04 13:00 ET
Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023 Financial Results; Revises Preliminary 2024 Revenue Outlook
2024-01-02 15:53 ET
Avanos Medical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07 18:08 ET
Avanos Medical, Inc. to Present at the Stifel 2023 Healthcare Conference
2023-11-01 11:00 ET
Avanos Medical, Inc. Announces Third Quarter 2023 Results
2023-10-25 13:30 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
2023-10-02 19:25 ET
AirLife Completes Acquisition of Avanos Medical’s Respiratory Health Business
2023-09-12 10:37 ET
Avanos Medical, Inc. to Present at the CL King Annual Best Ideas Conference
2023-08-09 11:00 ET
Avanos Medical, Inc. Announces Second Quarter 2023 Results
2023-08-08 22:52 ET
Avanos Medical, Inc. to Present at the UBS MedTech, Tools and Genomics Summit 2023
2023-08-02 16:31 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
2023-06-28 20:11 ET
Avanos Medical Supports New Interventional Procedure Recommendations from the UK's National Institute of Health and Care Excellence (NICE)
2023-06-19 17:00 ET
Avanos Medical, Inc. Announces Agreement to Acquire Diros Technology Inc.
2023-06-13 12:00 ET
Avanos Medical, Inc. To Host Investor Day on June 20, 2023
2023-06-08 10:55 ET
SunMed to Acquire Avanos Medical’s Respiratory Health Business
2023-06-08 10:50 ET
Avanos Medical, Inc. Announces Sale of Respiratory Health Business to SunMed Group Holdings, LLC
2023-05-03 11:00 ET
Avanos Medical, Inc. Announces First Quarter 2023 Results
2023-04-26 13:53 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2023 Financial Results
2023-03-15 11:42 ET
Avanos Medical, Inc. to Present at the 2023 Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
2023-03-06 12:00 ET
Avanos Medical, Inc. Appoints Dr. Lisa Egbuonu-Davis to Board of Directors
2023-02-21 12:00 ET
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2022 Results
2023-02-14 10:49 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
2023-01-11 12:15 ET
Avanos Medical, Inc. Announces New Leadership Appointments
2023-01-04 19:36 ET
Avanos Medical, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-11-14 12:15 ET
Avanos Medical, Inc. Appoints Sudhakar Varshney as Senior Vice President, Global Supply Chain & Procurement
2022-11-08 20:41 ET
Avanos Medical, Inc. to Present at the Stifel 2022 Healthcare Conference
2022-11-02 11:00 ET
Avanos Medical, Inc. Announces Third Quarter 2022 Results
2022-10-26 10:56 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
2022-09-07 11:31 ET
Avanos Medical, Inc. To Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-09 11:00 ET
Avanos Medical, Inc. Announces Second Quarter 2022 Results
2022-07-28 02:51 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
2022-05-17 14:54 ET
Avanos Medical, Inc. to Present at the UBS 2022 Global Healthcare Conference
2022-05-04 11:00 ET
Avanos Medical, Inc. Announces First Quarter 2022 Results
2022-04-27 17:38 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2022 Financial Results
2022-03-15 13:34 ET
Avanos Medical, Inc. to Present at the Virtual KeyBanc 2022 Life Sciences & MedTech Investor Forum
2022-02-23 12:00 ET
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2021 Results
2022-02-15 16:35 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
2022-01-10 14:07 ET
Avanos Medical, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-15 21:15 ET
Avanos Medical, Inc. Announces Share Repurchase Authorization
2021-12-13 21:05 ET
Avanos Medical, Inc. Announces Agreement To Acquire OrthogenRx, Inc.
2021-12-02 15:00 ET
Avanos Medical, Inc. Launches PainBlock Pro App
2021-11-02 11:00 ET
Avanos Medical, Inc. Announces Third Quarter 2021 Results
2021-10-26 11:00 ET
Avanos Medical, Inc. To Webcast Conference Call Discussing Third Quarter 2021 Financial Results
2021-08-03 11:00 ET
Avanos Medical, Inc. Announces Second Quarter 2021 Results
2021-07-27 11:00 ET
Avanos Medical, Inc. To Webcast Conference Call Discussing Second Quarter 2021 Financial Results
2021-07-12 11:15 ET
Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel
2021-06-18 11:00 ET
Avanos Medical, Inc. to Present at the 2021 Raymond James Human Health Innovation Conference
2021-05-07 11:00 ET
Avanos Medical, Inc. Announces First Quarter 2021 Results
2021-04-30 11:00 ET
Avanos Medical, Inc. To Webcast Conference Call Discussing First Quarter 2021 Financial Results
2021-03-16 11:00 ET
Avanos Medical, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum
2021-02-24 12:00 ET
Avanos Medical, Inc. to Present at the Virtual Raymond James 42nd Annual Institutional Investors Conference
2021-02-18 12:00 ET
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2020 Results
2021-02-11 12:00 ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full-Year 2020 Financial Results
2021-01-06 12:00 ET
Avanos Medical, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-11-05 12:00 ET
Avanos Medical, Inc. to Present at Two Virtual Investor Conferences in November
2020-11-03 12:00 ET
Avanos Medical, Inc. Announces Third Quarter 2020 Results
2020-10-27 11:00 ET
Avanos Medical, Inc. To Webcast Conference Call Discussing Third Quarter 2020 Financial Results
2020-09-15 11:00 ET
Avanos Medical, Inc. Appoints Michelle Scharfenberg as Senior Vice President & Chief Ethics and Compliance Officer
2020-09-04 11:00 ET
Avanos Medical, Inc. to Present at Two Virtual Investor Conferences in September
2020-09-03 11:00 ET
Avanos Medical, Inc. Announces Publication of Clinical Trial Demonstrating Superiority of COOLIEF* over Hyaluronic Acid Injections for the Management of Chronic Knee Pain
2020-08-31 20:01 ET
Avanos Medical, Inc. Appoints Bill Haydon as Senior Vice President & General Manager, Pain Franchise
2020-08-04 11:00 ET
Avanos Medical, Inc. Announces Second Quarter 2020 Results
2020-07-28 11:00 ET
Avanos Medical, Inc. To Webcast Conference Call Discussing Second Quarter 2020 Financial Results
2020-05-28 11:00 ET
Avanos Medical, Inc. to Present at Two Virtual Investor Conferences in June
2020-05-06 11:00 ET
Avanos Medical, Inc. Announces First Quarter 2020 Results and Provides an Update on its Response to the COVID-19 Pandemic
2020-04-29 11:00 ET
Avanos Medical, Inc. To Webcast Conference Call Discussing First Quarter 2020 Financial Results
2020-04-16 20:00 ET
Avanos Medical, Inc. Changes to Virtual Meeting Format for 2020 Annual Meeting of Stockholders
2020-02-25 12:00 ET
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2019 Results, Provides 2020 Outlook
2020-02-24 21:01 ET
Avanos Medical, Inc. Announces FDA Clearance of its New, 80-Watt COOLIEF* Radiofrequency System for Neurological Lesion Procedures
2020-02-24 12:00 ET
Avanos Medical, Inc. to Present at Two Investor Conferences in March
2020-02-11 12:00 ET
Avanos Medical, Inc. To Webcast Conference Call Discussing Fourth Quarter and Full-Year 2019 Financial Results
2020-01-08 12:00 ET
Avanos Medical, Inc. to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-11-13 12:00 ET
Avanos Medical, Inc. to Present at the Stifel 2019 Healthcare Conference
2019-11-05 12:00 ET
Avanos Medical, Inc. Announces Third Quarter 2019 Results, Completes Acquisition of Endoclear LLC
ET
WRS Group Announces Agreement to Acquire Avanos Medical's US Game Ready® Orthopedic Rental Business
ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
ET
Avanos Medical, Inc. Announces Third Quarter 2025 Results
ET
Avanos Medical Launches New CORGRIP® SR
ET
Avanos Medical, Inc. to Present at the UBS Healthcare Conference 2024
ET
ON-Q* Elastomeric Infusion Pump and ambIT* Disposable Electronic Infusion Pump to Receive Separate Payment Under NOPAIN Act Starting January 1, 2025
ET
Avanos Medical, Inc. to Present at the Stifel 2024 Healthcare Conference
ET
Avanos Medical, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
ET
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2024 Results
ET
Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer
ET
Avanos Expands Direct Operations for MIC-KEY* Enteral Feeding Products in the UK starting July 2025
ET
Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results
ET
Avanos Medical, Inc. Announces First Quarter 2025 Results
ET
Avanos Medical, Inc. Welcomes Camille Chang Gilmore as Senior Vice President and Chief Human Resources Officer
ET
Avanos Medical, Inc. to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
ET
Avanos Announces Divestiture of Hyaluronic Acid Product Line to Channel-Markers Medical
ET
Avanos Medical, Inc. Announces Second Quarter 2025 Results
ET
Avanos Medical Announces Appointment of Scott Galovan as Senior Vice President, Chief Financial Officer; David Pacitti Appointed to Board of Directors
ET
Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care

SEC forms

Show financial reports only

SEC form 10
2025-11-05 16:28 ET
Avanos Medical reported for 2025 q3
SEC form 8
2025-11-05 07:01 ET
Avanos Medical published news for 2025 q3
SEC form 8
2025-11-05 07:01 ET
Avanos Medical reported for 2025 q3
SEC form 10
2025-08-05 20:10 ET
Avanos Medical reported for 2025 q2
SEC form 8
2025-08-05 10:49 ET
Avanos Medical published news for 2025 q2
SEC form 8
2025-08-05 10:49 ET
Avanos Medical published news for 2025 q2
SEC form 8
2025-08-05 10:49 ET
Avanos Medical reported for 2025 q2
SEC form 8
2025-08-05 10:49 ET
Avanos Medical published news for 2025 q2
SEC form 8
2025-08-05 10:49 ET
Avanos Medical published news for 2025 q2
SEC form 10
2025-05-06 20:17 ET
Avanos Medical published news for 2025 q1
SEC form 8
2025-05-06 11:07 ET
Avanos Medical reported for 2025 q1
SEC form 8
2025-05-06 11:07 ET
Avanos Medical published news for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Avanos Medical published news for 2025 q1
SEC form 8
2025-04-25 18:02 ET
Avanos Medical published news for 2025 q1
SEC form 10
2025-02-26 21:55 ET
Avanos Medical published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Avanos Medical reported for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Avanos Medical published news for 2024 q4
SEC form 10
2025-02-26 00:00 ET
Avanos Medical published news for 2024 q4
SEC form 10
2024-10-30 16:17 ET
Avanos Medical reported for 2024 q3
SEC form 8
2024-10-30 06:55 ET
Avanos Medical reported for 2024 q3
SEC form 8
2024-10-30 06:55 ET
Avanos Medical published news for 2024 q3
SEC form 8
2024-10-30 06:55 ET
Avanos Medical published news for 2024 q3
SEC form 8
2024-10-30 06:55 ET
Avanos Medical published news for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Avanos Medical reported for 2024 q3
SEC form 10
2024-07-31 11:21 ET
Avanos Medical published news for 2024 q2
SEC form 8
2024-07-31 07:07 ET
Avanos Medical reported for 2024 q2
SEC form 8
2024-07-31 07:07 ET
Avanos Medical published news for 2024 q2
SEC form 10
2024-07-31 00:00 ET
Avanos Medical published news for 2024 q2
SEC form 10
2024-05-02 16:10 ET
Avanos Medical published news for 2024 q1
SEC form 8
2024-05-02 07:09 ET
Avanos Medical reported for 2024 q1
SEC form 8
2024-05-02 07:09 ET
Avanos Medical published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Avanos Medical published news for 2024 q1
SEC form 10
2024-02-21 00:00 ET
Avanos Medical published news for 2023 q4
SEC form 10
2024-02-20 18:33 ET
Avanos Medical published news for 2023 q4
SEC form 8
2024-02-20 07:05 ET
Avanos Medical published news for 2023 q4
SEC form 8
2024-02-20 07:05 ET
Avanos Medical reported for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Avanos Medical published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Avanos Medical published news for 2023 q4
SEC form 10
2023-11-01 16:09 ET
Avanos Medical published news for 2023 q3
SEC form 8
2023-11-01 07:14 ET
Avanos Medical reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Avanos Medical published news for 2023 q3
SEC form 10
2023-08-09 16:37 ET
Avanos Medical reported for 2023 q2
SEC form 6
2023-08-09 10:38 ET
Avanos Medical published news for 2023 q2
SEC form 6
2023-08-09 07:04 ET
Avanos Medical reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Avanos Medical published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Avanos Medical published news for 2023 q2
SEC form 6
2023-08-01 16:12 ET
Avanos Medical published news for 2023 q2
SEC form 6
2023-06-20 06:51 ET
Avanos Medical published news for 2023 q1
SEC form 6
2023-06-08 06:55 ET
Avanos Medical published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Avanos Medical published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Avanos Medical published news for 2023 q1
SEC form 8
2023-02-21 00:00 ET
Avanos Medical reported for 2022 q4
SEC form 10
2023-02-21 00:00 ET
Avanos Medical reported for 2022 q4
SEC form 10
2022-11-02 00:00 ET
Avanos Medical reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Avanos Medical reported for 2022 q3
SEC form 8
2022-08-09 00:00 ET
Avanos Medical reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Avanos Medical published news for
SEC form 8
2022-05-04 00:00 ET
Avanos Medical reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Avanos Medical reported for 2022 q1
SEC form 8
2022-02-23 00:00 ET
Avanos Medical published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Avanos Medical published news for 2021 q4
SEC form 8
2021-11-02 00:00 ET
Avanos Medical published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Avanos Medical published news for 2021 q3
SEC form 8
2021-08-03 00:00 ET
Avanos Medical published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Avanos Medical published news for 2021 q2
SEC form 8
2021-05-07 00:00 ET
Avanos Medical published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
Avanos Medical published news for 2021 q1